Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5136-5145

  Mensa, Bruk ^a   Howell, Gabriella L ^a   Scott, Richard ^b   DeGrado, William F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PolyMedix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL PEPTIDE LL16; BRILACIDIN; CHAPERONE; CYTOPLASM PROTEIN; DAPTOMYCIN; GRASR PROTEIN; NSASR PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; VRASR PROTEIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL PEPTIDE LL-37; BACTERIAL PROTEIN; CATHELICIDIN; PEPTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; CELL FUNCTION; CELL WALL; CELLULAR STRESS RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP SEQUENCING; DRUG STRUCTURE; GRAM POSITIVE BACTERIUM; MEMBRANE DEPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; TREATMENT RESPONSE; UPREGULATION; CYTOPLASM; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; VIRULENCE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CATHELICIDINS; CELL WALL; CYTOPLASM; DAPTOMYCIN; MICROBIAL SENSITIVITY TESTS; PEPTIDES; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION, GENETIC; VIRULENCE;

EID: 84906081308     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02955-14     Document Type: Article

References (64)

1. Opar A. 2007. Bad bugs need more drugs. Nat. Rev. Drug Discov. 6:943-944. http://dx.doi.org/10.1038/nrd2477. (Pubitemid 350201781)
2. Weinstein RA. 2001. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg. Infect. Dis. 7:188-192. http://dx.doi.org/10.3201/eid0702.010206. (Pubitemid 32374325)
3. Boman HG. 2000. Innate immunity and the normal microflora. Immunol. Rev. 173:5-16. http://dx.doi.org/10.1034/j.1600-065X.2000.917301.x. (Pubitemid 30095206)
4. Tossi A, Sandri L, Giangaspero A. 2000. Amphipathic, α-helical antimicrobial peptides. Biopolymers 55:4-30. http://dx.doi.org/10.1002/1097- 0282(2000)55:1〈4::AID-BIP30〉3.0.CO;2-M.
5. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a. (Pubitemid 34100944)
6. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. http://dx.doi.org/10. 1038/nrmicro1098. (Pubitemid 40298223)
7. Glukhov E, Burrows LL, Deber CM. 2008. Membrane interactions of designed cationic antimicrobial peptides: the two thresholds. Biopolymers 89:360-371. http://dx.doi.org/10.1002/bip.20917.
8. Hancock RE, Diamond G. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402-410. http://dx.doi.org/10.1016/ S0966-842X(00)01823-0.
9. Hancock RE, Rozek A. 2002. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol. Lett. 206:143-149. http://dx.doi.org/10.1111/j.1574-6968.2002.tb11000.x. (Pubitemid 34117610)
10. Powers JP, Hancock RE. 2003. The relationship between peptide structure and antibacterial activity. Peptides 24:1681-1691. http://dx.doi.org/10.1016/j. peptides.2003.08.023. (Pubitemid 38198075)
11. Perron GG, Zasloff M, Bell G. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc. Biol. Sci. 273:251-256. http://dx.doi.org/10. 1098/rspb.2005.3301. (Pubitemid 46768100)
12. Nizet V. 2006. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 8:11-26. (Pubitemid 43141388)
13. Schmitt MA, Weisblum B, Gellman SH. 2007. Interplay among folding, sequence, and lipophilicity in the antibacterial and hemolytic activities of alpha/beta-peptides. J. Am. Chem. Soc. 129:417-428. http://dx.doi.org/10.1021/ ja0666553. (Pubitemid 46106642)
14. Shandler SJ, Shapovalov MV, Dunbrack RL, Jr, DeGrado WF. 2010. Development of a rotamer library for use in beta-peptide foldamer computational design. J. Am. Chem. Soc. 132:7312-7320. http://dx.doi.org/10.1021/ja906700x.
15. Tew GN, Scott RW, Klein ML, Degrado WF. 2010. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc. Chem. Res. 43:30-39. http://dx.doi.org/10.1021/ ar900036b.
16. Choi S, Isaacs A, Clements D, Liu D, Kim H, Scott RW, Winkler JD, DeGrado WF. 2009. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U. S. A. 106:6968-6973. http://dx.doi.org/10.1073/pnas.0811818106.
17. Liu D, Choi S, Chen B, Doerksen RJ, Clements DJ, Winkler JD, Klein ML, DeGrado WF. 2004. Nontoxic membrane-active antimicrobial arylamide oligomers. Angew. Chem. Int. Ed. Engl. 43:1158-1162. http://dx.doi.org/10.1002/anie. 200352791. (Pubitemid 39257984)
18. Su Y, DeGrado WF, Hong M. 2010. Orientation, dynamics, and lipid interaction of an antimicrobial arylamide investigated by 19F and 31P solid-state NMR spectroscopy. J. Am. Chem. Soc. 132:9197-9205. http://dx.doi.org/10.1021/ja103658h.
19. Tew GN, Liu D, Chen B, Doerksen RJ, Kaplan J, Carroll PJ, Klein ML, DeGrado WF. 2002. De novo design of biomimetic antimicrobial polymers. Proc. Natl. Acad. Sci. U. S. A. 99:5110-5114. http://dx.doi.org/10.1073/pnas. 082046199. (Pubitemid 34411511)
20. Vilhena C, Bettencourt A. 2012. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev. Med. Chem. 12:202-209. http://dx.doi.org/10.2174/1389557511209030202.
21. Tew GN, Scott RW, Klein ML, DeGrado WF. 2010. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc. Chem. Res. 43:30-39. http://dx.doi.org/10.1021/ ar900036b.
22. Mensa B, Kim YH, Choi S, Scott R, Caputo GA, DeGrado WF. 2011. Antibacterial mechanism of action of arylamide foldamers. Antimicrob. Agents Chemother. 55:5043-5053. http://dx.doi.org/10.1128/AAC.05009-11.
23. Malli R, Epstein W. 1998. Expression of the Kdp ATPase is consistent with regulation by turgor pressure. J. Bacteriol. 180:5102-5108. (Pubitemid 28470936)
24. Asha H, Gowrishankar J. 1993. Regulation of kdp operon expression in Escherichia coli: evidence against turgor as signal for transcriptional control. J. Bacteriol. 175:4528-4537. (Pubitemid 23206956)
25. Laubacher ME, Ades SE. 2008. The Rcs phosphorelay is a cell envelope stress response activated by peptidoglycan stress and contributes to intrinsic antibiotic resistance. J. Bacteriol. 190:2065-2074. http://dx.doi.org/10.1128/ JB.01740-07. (Pubitemid 351355330)
26. Callewaert L, Vanoirbeek KG, Lurquin I, Michiels CW, Aertsen A. 2009. The Rcs two-component system regulates expression of lysozyme inhibitors and is induced by exposure to lysozyme. J. Bacteriol. 191:1979-1981. http://dx.doi.org/10.1128/JB.01549-08.
27. Danese PN, Snyder WB, Cosma CL, Davis LJ, Silhavy TJ. 1995. The Cpx two-component signal transduction pathway of Escherichia coli regulates transcription of the gene specifying the stress-inducible periplasmic protease, DegP. Genes Dev. 9:387-398. http://dx.doi.org/10.1101/gad.9.4.387.
28. Leblanc SK, Oates CW, Raivio TL. 2011. Characterization of the induction and cellular role of the BaeSR two-component envelope stress response of Escherichia coli. J. Bacteriol. 193:3367-3375. http://dx.doi.org/10.1128/JB. 01534-10.
29. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206-2214. (Pubitemid 28420351)
30. Senyurek I, Paulmann M, Sinnberg T, Kalbacher H, Deeg M, Gutsmann T, Hermes M, Kohler T, Gotz F, Wolz C, Peschel A, Schittek B. 2009. Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2499-2509. http://dx.doi.org/10.1128/AAC.01679-08.
31. Straus SK, Hancock RE. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223. http://dx.doi.org/10.1016/j.bbamem.2006.02.009. (Pubitemid 44436068)
32. Alborn WE, Jr, Allen NE, Preston DA. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287. http://dx.doi.org/10.1128/AAC.35.11.2282.
33. Allen NE, Alborn WE, Jr, Hobbs JN, Jr. 1991. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. 35:2639-2642. http://dx.doi.org/10.1128/AAC.35.12.2639.
34. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agents Chemother. 52:980-990. http://dx.doi.org/10. 1128/AAC.01121-07. (Pubitemid 351358377)
35. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Jr, Eliopoulos GM. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316. http://dx.doi.org/10.1371/journal. pone.0028316.
36. Boaretti M, Canepari P, Lleo MM, Satta G. 1993. The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J. Antimicrob. Chemother. 31:227-235. http://dx.doi.org/10.1093/jac/31.2.227. (Pubitemid 23092836)
37. Canepari P, Boaretti M, Lleo MM, Satta G. 1990. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. 34:1220-1226. http://dx.doi.org/10.1128/AAC.34.6. 1220. (Pubitemid 20177384)
38. Laganas V, Alder J, Silverman JA. 2003. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob. Agents Chemother. 47:2682-2684. http://dx.doi.org/10.1128/AAC.47.8.2682-2684.2003. (Pubitemid 36919481)
39. Kolar SL, Nagarajan V, Oszmiana A, Rivera FE, Miller HK, Davenport JE, Riordan JT, Potempa J, Barber DS, Koziel J, Elasri MO, Shaw LN. 2011. NsaRS is a cell-envelope-stress-sensing two-component system of Staphylococcus aureus. Microbiology 157:2206-2219. http://dx.doi.org/10.1099/mic.0.049692-0.
40. Belcheva A, Golemi-Kotra D. 2008. A close-up view of the VraSR two-component system. A mediator of Staphylococcus aureus response to cell wall damage. J. Biol. Chem. 283:12354-12364. http://dx.doi.org/10.1074/jbc. M710010200.
41. Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. 2007. Gram-positive three-component antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. U. S. A. 104:9469-9474. http://dx.doi.org/10.1073/pnas.0702159104. (Pubitemid 47185803)
42. Bisicchia P, Lioliou E, Noone D, Salzberg LI, Botella E, Hubner S, Devine KM. 2010. Peptidoglycan metabolism is controlled by the WalRK (YycFG) and PhoPR two-component systems in phosphate-limited Bacillus subtilis cells. Mol. Microbiol. 75:972-989. http://dx.doi.org/10.1111/j.1365-2958.2009.07036.x.
43. Bisicchia P, Noone D, Lioliou E, Howell A, Quigley S, Jensen T, Jarmer H, Devine KM. 2007. The essential YycFG two-component system controls cell wall metabolism in Bacillus subtilis. Mol. Microbiol. 65:180-200. http://dx.doi.org/10.1111/j.1365-2958.2007.05782.x. (Pubitemid 46938543)
44. Wiltshire MD, Foster SJ. 2001. Identification and analysis of Staphylococcus aureus components expressed by a model system of growth in serum. Infect. Immun. 69:5198-5202. http://dx.doi.org/10.1128/IAI.69.8.5198-5202.2001. (Pubitemid 32674512)
45. Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A. 2004. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol. Lett. 231:67-71. http://dx.doi.org/10.1016/S0378-1097(03)00921-2. (Pubitemid 38180561)
46. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. J. Bacteriol. 190:300-310. http://dx.doi.org/10.1128/JB.01000-07.
47. Stenglein MD, Sanders C, Kistler AL, Ruby JG, Franco JY, Reavill DR, Dunker F, Derisi JL. 2012. Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents for snake inclusion body disease. mBio 3(4):e00180-12. http://dx.doi.org/10.1128/mBio.00180-12.
48. Goecks J, Nekrutenko A, Taylor J. 2010. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11:R86. http://dx.doi.org/10.1186/gb-2010-11- 8-r86.
49. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, Nekrutenko A, Taylor J. 2010. Galaxy: a Web-based genome analysis tool for experimentalists. Curr. Protoc. Mol. Biol. Chapter 19: Unit 19.10.1-21. http://dx.doi.org/10.1002/0471142727.mb1910s89.
50. Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, Shah P, Zhang Y, Blankenberg D, Albert I, Taylor J, Miller W, Kent WJ, Nekrutenko A. 2005. Galaxy: a platform for interactive large-scale genome analysis. Genome Res. 15:1451-1455. http://dx.doi.org/10.1101/gr.4086505. (Pubitemid 41400913)
51. Li X, Li Y, Han H, Miller DW, Wang G. 2006. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J. Am. Chem. Soc. 128:5776-5785. http://dx.doi.org/10.1021/ja0584875. (Pubitemid 43724381)
52. Shapiro HM, Natale PJ, Kamentsky LA. 1979. Estimation of membrane potentials of individual lymphocytes by flow cytometry. Proc. Natl. Acad. Sci. U. S. A. 76:5728-5730. http://dx.doi.org/10.1073/pnas.76.11.5728. (Pubitemid 10168679)
53. Bennett S. 2004. Solexa Ltd. Pharmacogenomics 5:433-438. http://dx.doi.org/10.1517/14622416.5.4.433. (Pubitemid 38923657)
54. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Cheetham RK, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, et al. 2008. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53-59. http://dx.doi.org/10.1038/ nature07517.
55. Delaune A, Dubrac S, Blanchet C, Poupel O, Mader U, Hiron A, Leduc A, Fitting C, Nicolas P, Cavaillon JM, Adib-Conquy M, Msadek T. 2012. The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response. Infect. Immun. 80:3438-3453. http://dx.doi.org/10.1128/IAI.00195-12.
56. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49:807-821. http://dx.doi.org/10.1046/j.1365-2958.2003.03599.x. (Pubitemid 36918698)
57. Kawada-Matsuo M, Yoshida Y, Zendo T, Nagao J, Oogai Y, Nakamura Y, Sonomoto K, Nakamura N, Komatsuzawa H. 2013. Three distinct two-component systems are involved in resistance to the class I bacteriocins, nukacin ISK-1 and nisin A, in Staphylococcus aureus. PLoS One 8:e69455. http://dx.doi.org/10. 1371/journal.pone.0069455.
58. Yoo JI, Kim JW, Kang GS, Kim HS, Yoo JS, Lee YS. 2013. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus. J. Microbiol. 51:160-165. http://dx.doi.org/10.1007/s12275-013-3088-7.
59. Kato Y, Suzuki T, Ida T, Maebashi K. 2010. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. J. Antimicrob. Chemother. 65:37-45. http://dx.doi.org/10.1093/jac/dkp394.
60. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53:3375-3383. http://dx.doi.org/10.1128/AAC.01710-08.
61. Song Y, Lunde CS, Benton BM, Wilkinson BJ. 2012. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob. Agents Chemother. 56:3157-3164. http://dx.doi.org/10.1128/AAC.05403-11.
62. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06819.x.
63. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410. http://dx.doi.org/10.1074/jbc.274.13.8405. (Pubitemid 29164628)
64. Falord M, Karimova G, Hiron A, Msadek T. 2012. GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 56:1047-1058. http://dx.doi.org/10.1128/AAC.05054- 11.